Arrowfly launched its Medical Design & Outsourcing Medtech Innovation Board, an invitation-only medical device innovation community that brings together experts from device developers, manufacturers and their supply chain partners to collaborate on the trends, technologies and challenges shaping the future of healthcare.
As part of Arrowfly’s new Industry Leadership Boards initiative, the MDO Medtech Innovation Board will hold quarterly meetings of engineers and leaders from medical device developers and medtech materials, development and manufacturing outsourcing partners for conversations that will yield actionable advice to accelerate innovation across the entire medical device industry.
This board has unique expertise in minimally invasive implants and therapies for conditions like heart disease, diabetes and hypertension, including electrophysiology, structural heart and cardiac rhythm, robotics, renal denervation, neuromodulation, drug delivery, imaging and the advanced materials and manufacturing processes that make them possible.
The inaugural board’s members are:
- Jim Hammerand, managing editor at Medical Design & Outsourcing and founding chair of the MDO Medtech Innovation Board
- Ashish Bhargava, VP of global research & development at Phillips Medisize
- April Butterfield, SVP of technology at Jabil
- Matthew Fishler, chief engineer and director of systems engineering for the leadless pacemaker platform at Abbott
- Jason Fontana, former VP and GM of renal denervation at Medtronic
- Maria Grahm, global VP for life sciences at Siemens
- Deanna Harshbarger, CEO at Cala Health
- Bill Hunter, president, CEO and chief medical officer at Canary Medical
- Ryan James, co-founder and CEO of Dopl Technologies
- Eric Leopold, VP of product development at Aptyx
- Jose Maeso, CTO at Lighteum
- Sean McNulty, global VP of R&D for electrophysiology at Boston Scientific
- Darshin Patel, VP of aortic regurgitation at Edwards Lifesciences
- Stacey Pugh, CEO at Endogenex
- Scott Robertson, VP of nitinol technology at Resonetics
- Katie Schindler, medical device innovation leader at Mitsubishi Chemical Group
- Luke Wellington, associate VP for drug delivery systems and medical device development at Eli Lilly
- Shane Wood, director of technology, polymers at Confluent
Convened by Arrowfly’s editorial leadership, board members will participate in quarterly meetings focused on emerging technologies, regulatory developments, customer needs, and the innovations transforming medical technology. Throughout the year, members will also have opportunities to contribute to interviews, podcasts, articles, webinars, and other thought leadership initiatives that provide valuable insights for the broader medtech community.
“Our industry is driven by innovators who care deeply about saving and improving lives,” Jim Hammerand said. “MDO’s mission is to highlight innovation that inspires and empowers device developers to succeed, and the members of this board have stepped up to help our industry bring new and improved products to physicians and patients.”
In addition to exclusive networking and collaboration opportunities, board members receive year-round visibility through Arrowfly’s editorial platforms, board communications, website recognition, and industry content designed to showcase the expertise of participating organizations.
“The MDO Medtech Innovation Board represents the collective genius of the medical device industry. When you connect people across the entire value chain, you accelerate progress. For Arrowfly, it’s an opportunity to strengthen partnerships and help our entire ecosystem move faster,” said Amanda Buehner, Senior Vice President, Sales & Strategy, Engineering, Arrowfly.
The MDO Medtech Innovation Board reflects Arrowfly’s commitment to creating leadership communities that encourage meaningful collaboration, elevate industry expertise, and help shape the future of medical technology through trusted editorial leadership.